Predictors of functional benefit of hepatitis C therapy in a ‘real-life’ cohort

doi:10.3748/wjg.v24.i7.852

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 24, Issue 7

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (9247)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-3) series.

Item

Count

PDF

578

WORD

297

HTML

4312

Figures (1-3)

303

Tables (1-3)

285

Sum=5775

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1524

Download

1948

Sum=3472

Feb 21, 2018 (publication date) through Feb 21, 2025

Times Cited of This Article

Times Cited (2)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastroenterol. Feb 21, 2018; 24(7): 852-861
Published online Feb 21, 2018. doi: 10.3748/wjg.v24.i7.852

Table 2 Therapy regime and treatment duration

Therapy regime	Treatment duration (wk)	GT 1	GT 2	GT 3	GT 4
SOF + RBV	12	2 (1)	5 (3)
SOF + RBV	24	11 (5)		18 (9)
SOF + LDV	12				1 (1)
SOF + LDV + RBV	12	73 (36)			2 (1)
SOF + LDV + RBV	24	14 (6)		3 (2)
SOF + DCV	12	2 (1)		1 (1)
SOF + DCV	24	19 (9)
SOF + DCV + RBV	12	3 (2)	2 (1)	1 (1)
SOF + DCV + RBV	24	3 (2)		7 (3)
SOF + SMV	12	13 (6)			3 (2)
SOF + SMV + RBV	12	2 (1)
PTV/r + OMV + DSV	12	8 (4)
PTV/r + OMV + DSV + RBV	12	6 (3)

Data are expressed as number of patients for each therapy regime (percent of total patients). GT: Genotype, SOF: Sofosbuvir; RBV: Ribavirin; LDV: Ledipasvir; DCV: Daclatasvir; SMV: Simeprevir; PTV/r: Paritaprevir/ritonavir; OMV: Ombitasvir; DSV: Dasabuvir.

Citation: Steinebrunner N, Stein K, Sandig C, Bruckner T, Stremmel W, Pathil A. Predictors of functional benefit of hepatitis C therapy in a ‘real-life’ cohort. World J Gastroenterol 2018; 24(7): 852-861
URL: https://www.wjgnet.com/1007-9327/full/v24/i7/852.htm
DOI: https://dx.doi.org/10.3748/wjg.v24.i7.852